All individual numbers are from the SEC provided Financial Statement and Notes Data Sets. No guarantee is made for their accuracy. This report only shows the values that are common to a significant number of companies.
ANGION BIOMEDICA CORP. Last Reported: 8/31/2021 Stock Symbol: ANGN

Business Address

51 CHARLES LINDBERGH BOULEVARD

UNIONDALE, NY US 11553

Mailing Address

51 CHARLES LINDBERGH BOULEVARD

UNIONDALE, NY US 11553
Phone Number: (415) 655-4899 / State Incorporated: DE / Fiscal Year End 12/31

Balance Sheet

Date 6/30/2021 3/31/2021 1/31/2021 12/31/2020 6/30/2020 3/31/2020 12/31/2019
Cash and Cash Equivalents $117,300,000.00 $130,500,000.00 -- $34,607,000.00 -- -- --
Accounts Receivable Net Current -- -- -- -- -- -- --
Inventory -- -- -- -- -- -- --
Prepaid Expenses and Other Current Assets $2,389,000.00 $3,042,000.00 -- $7,690,000.00 -- -- --
Total Current Assets $119,702,000.00 $133,498,000.00 -- $42,297,000.00 -- -- --
Property Plant and Equipement $412,000.00 $246,000.00 -- $156,000.00 -- -- --
Intangible Assets Net -- -- -- -- -- -- --
Goodwill -- -- -- -- -- -- --
Other Assets $38,000.00 $38,000.00 -- -- -- -- --
Total Assets $125,359,000.00 $139,200,000.00 -- $47,347,000.00 -- -- --
Accounts Payable $9,307,000.00 $6,690,000.00 -- $5,578,000.00 -- -- --
Accrued Liabilities $4,675,000.00 $4,092,000.00 -- $6,665,000.00 -- -- --
Total Current Liabilities $48,170,000.00 $46,757,000.00 -- $137,796,000.00 -- -- --
Long Term Debt -- -- -- -- -- -- --
Additional Paid-in Capital -- -- -- -- -- -- --
Accumulated Other Comprehensive Loss $-219,000.00 $-287,000.00 -- $-333,000.00 -- -- --
Accumulated Deficit $-214,321,000.00 $-197,200,000.00 -- $-160,562,000.00 -- -- --
Total Stockholders' Equity $77,189,000.00 $92,443,000.00 -- $-90,449,000.00 $-49,097,000.00 $-30,676,000.00 $-18,586,000.00
Controlling Interest in Subsidiaries -- -- -- -- -- -- --
Total Liabilities and Equity $125,359,000.00 $139,200,000.00 -- $47,347,000.00 -- -- --

Statement of Operations

Date 6/30/2021 3/31/2021 1/31/2021 12/31/2020 6/30/2020 3/31/2020 12/31/2019
Total Revenues $911,000.00 $371,000.00 -- -- $729,000.00 $865,000.00 --
Cost of Revenues -- -- -- -- $716,000.00 $383,000.00 --
Gross Profit -- -- -- -- -- -- --
Research and Development $28,742,000.00 $14,298,000.00 -- -- $12,230,000.00 $9,596,000.00 --
Selling, General, and Administrative -- -- -- -- -- -- --
Total Operating Expenses -- -- -- -- -- -- --
Loss from Operations $-38,183,000.00 $-19,939,000.00 -- -- $-29,838,000.00 $-12,569,000.00 --
Loss Before Income Taxes -- -- -- -- -- -- --
Earnings Per Share Basic $-2.02 $-1.56 -- -- $-2.32 $-0.91 --
Weighted Average Shares Basic 29,670,329 23,443,851 -- -- 14,488,746 14,462,823 --
Earnings Per Share Diluted $-2.02 $-1.56 -- -- $-2.32 $-0.91 --
Weighted Average Shares Diluted 26,574,290 23,443,851 -- -- 14,514,670 14,462,823 --
Common Stock Shares Authorized 300,000,000 300,000,000 300,000,000 300,000,000 -- -- --
Common Stock Shares Outstanding 29,797,587 29,660,458 -- 15,316,721 -- -- --
Common Stock Value $303,000.00 $300,000.00 -- $156,000.00 -- -- --
Common Stock Par Or Stated Value Per Share $0.01 $0.01 $0.01 $0.01 -- -- --
Payments Of Dividends Common Stock -- -- -- -- -- -- --
Preferred Stock Shares Authorized -- -- 10,000,000 -- -- -- --
Preferred Stock Shares Outstanding -- -- -- -- -- -- --
Preferred Stock Value -- -- -- -- -- -- --
Preferred Stock Par Or Stated Value Per Share -- -- $0.01 -- -- -- --
Share Price -- -- -- -- -- -- --
Copyright 2021 PursePoor.com